Russian COVID vaccine: Dr Reddys likely to submit Sputnik light trial data to DCGI in November

Published On 2021-10-30 05:30 GMT   |   Update On 2021-10-30 13:18 GMT
Advertisement

New Delhi: Dr. Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18-year-old children in two cohorts.

Deepak Sapra CEO – API and Services Dr. Reddy's said the drugmaker is in discussions with the Drug Controller General of India to conduct trials on introducing Sputnik V as a booster dose.

Advertisement

He also said Dr. Reddy is trying to engage in discussions with the Centre for Sputnik V Government supplies even as the company sees "softness" in the off-take of the vaccine in the private sector.

"As far as Sputnik Light is concerned we are in the midst of our clinical trials and we expect that we can update post our submission to the DCGI in November.

As far as Sputnik as a booster dose is concerned, we have finalized our protocol. We are in discussions with DCGI for initiating the trials for Sputnik booster dose," Sapra said in a virtual press conference.

In addition to servicing the Indian requirements, Dr. Reddy is in discussions with its partners to take the jab to other countries notably in Asia-Pacific, Africa, and Latin America, he further said.

"We are seeing softness in the off-take of the vaccine in the private sector in India," the official said.

According to the recommendations of the SEC meeting held in August last, Dr. Reddy's, which has tied up with the Russian Direct Investment Fund to market the jab in India, presented updated safety, immunogenicity, and efficacy data of Phase III clinical trial of Sputnik Light vaccine conducted in Russia, along with the proposal to conduct the clinical trial in India.

The trials of Sputnik as booster dose and pediatric dose are being conducted by RDIF outside India, Sapra explained adding that the trials in India may take off in November.

Read also: COVID-19: WHO continues to assess Sputnik V vaccine

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News